According to The Insight Partners, the global somatostatin market size is projected to reach US$ 1,096.69 million by 2034 from US$ 431.86 million in 2025. The market is anticipated to register a CAGR of 10.91% during the forecast period 2026-2034. This growth reflects rising diagnosis rates of hormone-related disorders, increasing demand for targeted peptide therapies, and continued investment in long-acting formulations that improve patient adherence and outcomes.

Somatostatin is a peptide hormone that regulates the endocrine system and inhibits the release of several other hormones, including growth hormone, insulin, and glucagon. Synthetic analogs are widely used to manage acromegaly, carcinoid syndrome, and gastroenteroPancreatic neuroendocrine tumors. As clinicians increasingly favor treatments that provide sustained hormonal control with fewer side effects, somatostatin analogs are becoming a cornerstone of care in endocrinology and oncology.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00027878

Somatostatin Market Size, Share, Trends, Analysis and Forecast by 2034

Market Size: The global market is expected to grow from US$ 431.86 million in 2025 to US$ 1,096.69 million by 2034, more than doubling over the forecast period.
Market Share: Established players with long-acting injectable portfolios hold a significant share, while emerging companies are gaining ground with oral and novel delivery options.
Market Trends: Development of oral somatostatin receptor agonists, extended-release depot injections, and peptide receptor radionuclide therapies is reshaping treatment approaches.
Market Analysis: Rising incidence of neuroendocrine tumors, better diagnostic imaging, and growing specialist awareness are the primary demand drivers.
Market Forecast: The market is projected to expand at a CAGR of 10.91% from 2026 to 2034, supported by pipeline advancements and expanding patient access.
Key Players in the Somatostatin Market

The competitive landscape features a mix of global pharmaceutical leaders and specialized peptide developers, all focused on expanding portfolios, improving drug delivery, and strengthening clinical evidence. Key players profiled in the market include:

Novartis AG
Sun Pharmaceutical Industries Ltd
Midatech Pharma PLC
Ipsen Pharma
Chiasma Inc.
Peptron, Inc
Crinetics Pharmaceuticals
Dauntless Pharmaceuticals
Camurus AB
Teva Pharmaceuticals Inc,
Pfizer Inc.
These companies are pursuing strategies such as product innovation, strategic collaborations, licensing agreements, and geographic expansion to strengthen their positions. Investment in next-generation formulations, including oral and long-acting options, is expected to intensify competition and broaden treatment choices for patients and physicians through 2034.

Regional Analysis

North America: The region benefits from a strong healthcare system, significant research and development spending, and rapid uptake of new therapies. The United States leads regional demand, while Canada contributes through improving access to specialty treatments and growing clinical research activity.

Europe: Europe holds a considerable position, driven by well-established endocrinology networks, supportive public healthcare systems, and the presence of leading peptide developers. Countries such as Germany, France, the UK, Italy, and Spain are key contributors, with rising diagnosis rates supporting steady growth.

Asia Pacific: Asia Pacific is expected to register robust growth as healthcare access improves and awareness of rare endocrine and oncologic conditions rises. China, Japan, India, and South Korea are focus markets, backed by expanding pharmaceutical manufacturing capabilities and growing healthcare expenditure.

South and Central America: Growth in this region is supported by gradually improving healthcare infrastructure and increasing availability of specialty drugs. Brazil and Argentina lead regional demand, though affordability and reimbursement remain areas for improvement.

Middle East and Africa: The region is at an earlier stage of market development, but investments in healthcare modernization and rising awareness of chronic and rare diseases are creating new opportunities, particularly in the GCC countries and South Africa.

Future Outlook

The somatostatin market is entering a period of sustained expansion, shaped by therapeutic innovation, a growing patient pool, and increasing preference for targeted peptide treatments. With the market projected to reach US$ 1,096.69 million by 2034, stakeholders that invest in differentiated formulations, expand access, and build strong clinical evidence will be well placed to capture emerging opportunities.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: [email protected]
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish